Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK.
作者信息
Nadesalingam Angalee, Cantoni Diego, Wells David A, Aguinam Ernest T, Ferrari Matteo, Smith Peter, Chan Andrew, Carnell George, Ohlendorf Luis, Einhauser Sebastian, George Charlotte, Wagner Ralf, Temperton Nigel, Castillo-Olivares Javier, Baxendale Helen, Heeney Jonathan L
机构信息
Laboratory of Viral Zoonotics, University of Cambridge, Cambridge CB3 OES, UK.
Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Medway, UK.
出版信息
Lancet Microbe. 2021 Sep;2(9):e416-e418. doi: 10.1016/S2666-5247(21)00157-9. Epub 2021 Jun 28.
Abstract
摘要
相似文献
1
Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK.英国接种疫苗的免疫缺陷患者和医护人员对新冠病毒变异株的中和抗体反应不足且不一致。
Lancet Microbe. 2021 Sep;2(9):e416-e418. doi: 10.1016/S2666-5247(21)00157-9. Epub 2021 Jun 28.
2
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.T 细胞和抗体对先前感染和 SARS-CoV-2 阴性的英国医护人员第一剂 BNT162b2 疫苗的反应：一项多中心前瞻性队列研究。
Lancet Microbe. 2022 Jan;3(1):e21-e31. doi: 10.1016/S2666-5247(21)00275-5. Epub 2021 Nov 9.
3
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.BNT162b2 新冠病毒疫苗与体液免疫应答及动力学的相关性：医护人员前瞻性、单中心、纵向队列研究。
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
4
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.COVID-19 康复者感染后 1 年的 SARS-CoV-2 特异性抗体和 T 细胞反应：一项纵向队列研究。
Lancet Microbe. 2022 May;3(5):e348-e356. doi: 10.1016/S2666-5247(22)00036-2. Epub 2022 Mar 23.
5
SARS-CoV-2 neutralising antibody therapies: Recent advances and future challenges.SARS-CoV-2 中和抗体疗法：最新进展与未来挑战。
Rev Med Virol. 2023 Sep;33(5):e2464. doi: 10.1002/rmv.2464. Epub 2023 Jun 15.
6
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.英国血液透析患者新冠病毒疫苗接种后的中和抗体
Lancet. 2021 Sep 18;398(10305):1038-1041. doi: 10.1016/S0140-6736(21)01854-7. Epub 2021 Aug 13.
7
Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.测定 COVID-19 恢复期供者体内中和抗 SARS-CoV-2 抗体半衰期。
Clin Immunol. 2021 Nov;232:108871. doi: 10.1016/j.clim.2021.108871. Epub 2021 Oct 4.
8
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers.英国和南非严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）变异株在接受 BNT162b2 疫苗接种或新冠肺炎（COVID-19）康复的医护人员中的中和异质性。
Clin Infect Dis. 2022 Mar 1;74(4):707-710. doi: 10.1093/cid/ciab492.
9
Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.既往感染对长期护理机构接种疫苗工作人员中 SARS-CoV-2 抗体反应的影响。
mSphere. 2022 Aug 31;7(4):e0016922. doi: 10.1128/msphere.00169-22. Epub 2022 Jul 5.
10
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.恢复期血浆疗法治疗 COVID-19 患者：抗体检测方法评估及其与中和抗体水平的相关性。
Transfus Med. 2021 Jun;31(3):167-175. doi: 10.1111/tme.12746. Epub 2020 Dec 17.
引用本文的文献
1
Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population.伊朗人群中 COVID-19 疫苗的免疫原性和不良反应在健康人群和自身免疫性疾病患者中的表现。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241239202. doi: 10.1177/03946320241239202.
2
Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.免疫缺陷患者中，mRNA疫苗与腺病毒载体新冠疫苗诱导的T细胞和抗体反应差异
J Allergy Clin Immunol Glob. 2023 May;2(2):100091. doi: 10.1016/j.jacig.2023.100091. Epub 2023 Mar 15.
3
Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group.西班牙成年人社区获得性肺炎疫苗接种：NeumoExperts预防小组的实用建议
Antibiotics (Basel). 2023 Jan 10;12(1):138. doi: 10.3390/antibiotics12010138.
4
Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.先前感染 SARS-CoV-2 后接种 ChAdOx1 nCoV-19 对 COVID-19 的保护免疫：体液和细胞研究。
Viruses. 2022 Aug 30;14(9):1916. doi: 10.3390/v14091916.
5
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study.接种疫苗前 SARS-CoV-2 再感染的抗体保护相关性：SIREN 研究中的嵌套病例对照研究。
J Infect. 2022 Nov;85(5):545-556. doi: 10.1016/j.jinf.2022.09.004. Epub 2022 Sep 9.
6
SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol.心血管危险因素患者的 SARS-CoV-2 体液免疫反应：社区队列研究方案。
BMJ Open. 2022 May 19;12(5):e061345. doi: 10.1136/bmjopen-2022-061345.
7
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.异源接种灭活疫苗后再接种 mRNA 加强针可诱导针对 SARS-CoV-2 奥密克戎变异株的强烈免疫应答。
Nat Commun. 2022 May 13;13(1):2670. doi: 10.1038/s41467-022-30340-5.
8
AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.阿斯利康的 COVID-19 疫苗在马拉维既往感染过 SARS-CoV-2 的成年人中诱导出强大的广泛交叉反应性抗体应答。
BMC Med. 2022 Mar 28;20(1):128. doi: 10.1186/s12916-022-02342-z.
9
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.根据 BNT162b2 疫苗接种和感染史，抗 SARS-CoV-2 免疫球蛋白同种型和对病毒变异体的中和活性。
Front Immunol. 2021 Dec 17;12:793191. doi: 10.3389/fimmu.2021.793191. eCollection 2021.
10
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.COVID-19 疫苗接种在妊娠、儿科、免疫功能低下患者以及有过敏史或既往 SARS-CoV-2 感染史的人群中的应用：当前推荐意见概述，以及疫苗有效性和安全性的上市前和上市后证据。
Drug Saf. 2021 Dec;44(12):1247-1269. doi: 10.1007/s40264-021-01131-6. Epub 2021 Nov 5.
本文引用的文献
1
Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）慢病毒假型的生产、滴定、中和、储存及冻干
Bio Protoc. 2021 Nov 5;11(21):e4236. doi: 10.21769/BioProtoc.4236.
2
The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and sex profile of COVID-19 mortality: A population based ecological study.巴西亚马孙地区新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株P.1的出现与新冠肺炎死亡的年龄和性别分布变化在时间上相关：一项基于人群的生态学研究。
Lancet Reg Health Am. 2021 Sep;1:100021. doi: 10.1016/j.lana.2021.100021. Epub 2021 Jul 13.
3
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.有证据表明，在接种 BNT162b2 mRNA 疫苗的人群中，SARS-CoV-2 变异株的突破性感染率有所增加。
Nat Med. 2021 Aug;27(8):1379-1384. doi: 10.1038/s41591-021-01413-7. Epub 2021 Jun 14.
4
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.BNT162b2新冠疫苗对B.1.1.7和B.1.351变异株的有效性
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
5
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.英格兰医护人员的 COVID-19 疫苗接种率和 BNT162b2 mRNA 疫苗对感染的有效性（SIREN）：一项前瞻性、多中心、队列研究。
Lancet. 2021 May 8;397(10286):1725-1735. doi: 10.1016/S0140-6736(21)00790-X. Epub 2021 Apr 23.
6
Covid-19: Infections fell by 65% after first dose of AstraZeneca or Pfizer vaccine, data show.新冠疫情：数据显示，接种第一剂阿斯利康或辉瑞疫苗后，感染率下降了65%。
BMJ. 2021 Apr 23;373:n1068. doi: 10.1136/bmj.n1068.
7
Antibody evasion by the P.1 strain of SARS-CoV-2.SARS-CoV-2 P.1 株的抗体逃逸。
Cell. 2021 May 27;184(11):2939-2954.e9. doi: 10.1016/j.cell.2021.03.055. Epub 2021 Mar 30.
8
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.SARS-CoV-2 变体 B.1.351 从自然和疫苗诱导的血清中逃逸的证据。
Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.
9
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
10
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.社区检出的 SARS-CoV-2 谱系 B.1.1.7 病例死亡率增加。
Nature. 2021 May;593(7858):270-274. doi: 10.1038/s41586-021-03426-1. Epub 2021 Mar 15.
Zotero 插件